RxDoctor Payments Data

Abhijit Kanthala, MD

Internal Medicine · Dalton, GANPI 1730443383

Payments from drug & device makers

$430in general payments, 2019–2025

Across 19 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$148
  • AstraZeneca$69
  • Novo Nordisk$60
  • AbbVie$27
  • Boston Scientific$24
  • Esperion Therapeutics, Inc.$22
  • plus $80 from 5 others

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$430 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$109,162
Medicare patients
361
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$131,847
RexultiBrexpiprazole33$48,190
JardianceEmpagliflozin68$38,473
OzempicSemaglutide37$36,839
FarxigaDapagliflozin Propanediol67$33,695
XareltoRivaroxaban59$31,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,820
EntrestoSacubitril/Valsartan44$22,094
TrulicityDulaglutide19$18,551
JanuviaSitagliptin Phosphate35$17,059
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog102$14,191
Tresiba Flextouch U-200Insulin Degludec28$13,151
Risperdal ConstaRisperidone Microspheres23$12,369
Breo ElliptaFluticasone/Vilanterol28$12,077
MyrbetriqMirabegron25$11,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$20$48,19033 claims
AstraZenecaFarxiga, Breztri Aerosphere$69$43,51882 claims
Novo NordiskOzempic, Levemir$60$39,10955 claims
Lilly USA, LLCTrulicity$13$18,55119 claims
AbbVieLumigan$27$3,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →